About C-X-C chemokine receptor type 5
C-X-C chemokine receptor type 5 (CXCR5) is a protein
from Homo sapiens identified by UniProt accession
P32302, 372 residues long.
MolForge cross-references it against 0 known binders and
497 disease associations.
Target properties
| Protein name | C-X-C chemokine receptor type 5 |
|---|
| UniProt accession | P32302 |
|---|
| Gene | CXCR5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 372 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (497)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.22
- allergic rhinitis · score 0.21
- primary biliary cirrhosis · score 0.20
- childhood onset asthma · score 0.20
- allergic disease · score 0.19
- leukocyte count · score 0.18
- atopic eczema · score 0.17
- anti-human herpes virus 7 antibody measurement · score 0.17
- albumin:globulin ratio measurement · score 0.16
- asthma · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P32302-F1 | alphafold | PREDICTED | 81.11 | — |
Amino-acid sequence (372 residues)
MNYPLTLEMD LENLEDLFWE LDRLDNYNDT SLVENHLCPA TEGPLMASFK AVFVPVAYSL IFLLGVIGNV LVLVILERHR QTRSSTETFL FHLAVADLLL VFILPFAVAE GSVGWVLGTF LCKTVIALHK VNFYCSSLLL ACIAVDRYLA IVHAVHAYRH RRLLSIHITC GTIWLVGFLL ALPEILFAKV SQGHHNNSLP RCTFSQENQA ETHAWFTSRF LYHVAGFLLP MLVMGWCYVG VVHRLRQAQR RPQRQKAVRV AILVTSIFFL CWSPYHIVIF LDTLARLKAV DNTCKLNGSL PVAITMCEFL GLAHCCLNPM LYTFAGVKFR SDLSRLLTKL GCTGPASLCQ LFPSWRRSSL SESENATSLT TF
Explore C-X-C chemokine receptor type 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets